Thursday, November 17, 2016 7:42:23 PM
John Bourque's non-official Bourque Industries status communication to the shareholders via his private person Twitter tweets has hearsay of a dozen or two ballistic plate sales to law enforcement, that plus hearsay on this board of a gift of ballistic plates, has the resulting fact that Bourque Industries has no sales as verifiable by the shareholders.
From the last financial: FISCAL YEAR ENDED MAY 31, 2016
[Bourque Industries] has recurring losses, an accumulated deficient of over $42,000,000.00 [and no] material working capital [or] reliable source of funding.
[Bourque Industries] had no substantial sales in the fiscal year ended May 31, 2016 nor in any of the fiscal years ended May 31, 2014 or 2015.
Third parties may violate [Bourque Industries] rights to its intellectual property, including the Company’s patents and trade secrets; if the Company needs to institute or defend legal proceedings involving intellectual property or other rights the Company would be require to raise capital to prosecute or defend such actions; [currently based on above facts available to the shareholders, Bourque Industries is not able to do so,] placing its primary assets in jeopardy;
Question: Why would the Board of Directors at Bourque Industries allow the above official status to prevail as current, if such has changed, thus allowing BORK's pps $0.005 for Volume 2,184,169 to speak as status looking forward.
Also,
Since August 22, 2012, the securities of Bourque Industries, Inc. (the "Issuer" or the "Company") have been under a "chill" by the Depository Trust Company (DTC). A DTC chill prevents additional deposits of the issuer's securities for depository and book entry transfer services. As a result, shares are not available by computer or electronic transfer
d
The posts contained on my (gotmilk) account are my own opinions and are not recommendations or advise to buy or sell any security, stocks or other investments. These posts are for entertainment purposes only and are not considered to be facts or truth.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM